消化管間質腫瘍治療の世界市場2019-2023

◆英語タイトル:Global Gastrointestinal Stromal Tumors Therapeutics Market 2019-2023
◆商品コード:IRTNTR31341
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年5月17日
◆ページ数:128
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:米州、アジア、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、消化管間質腫瘍治療の世界市場について調べ、消化管間質腫瘍治療の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、消化管間質腫瘍治療の市場規模をセグメンテーション別(投与経路別(経口、非経口)、)と地域別(米州、アジア、ヨーロッパ(EMEA))に分けて算出しました。Technavio社は消化管間質腫瘍治療の世界市場規模が2019-2023期間中に年平均6%成長すると予測しています。
・サマリー
・レポートの範囲
・消化管間質腫瘍治療の市場状況
・消化管間質腫瘍治療の市場規模
・消化管間質腫瘍治療の市場予測
・消化管間質腫瘍治療の世界環境:ファイブフォース分析
・市場セグメンテーション:投与経路別(経口、非経口)
・消化管間質腫瘍治療の顧客状況
・主要地域別市場規模:米州、アジア、ヨーロッパ(EMEA)
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

About this market

The gastrointestinal stromal tumors therapeutics market has witnessed an increase in the use of therapeutics. The demand for therapeutics is expected to increase owing to the increasing advances in the research of targeted checkpoint inhibitors such as programmed cell death protein 1 (PD-1) inhibitors and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors. For instance, the market is expected to benefit significantly from the anticipated launch of KEYTRUDA, a novel PD-1 inhibitor by Merck, during the first half of the forecast period. The drug has shown superior efficacy in the clinical stages for the treatment of gastrointestinal stromal tumors. Also, these drugs are already approved for other indications and have been maintaining a blockbuster status. This would help these drugs to penetrate fast in the global gastrointestinal stromal tumors therapeutics market after their approval and launch, thereby increasing the adoption of therapeutics during the forecast period. Technavio’s analysts have predicted that the gastrointestinal stromal tumors therapeutics market will register a CAGR of over 6% by 2023.

Market Overview

Increasing awareness campaigns

Gastrointestinal stromal tumors are a rare type of cancer; hence, the awareness of the disease is deficient among the people. As a result, the diagnosis of the indication is often delayed until the late stages due to the lack of knowledge of the symptoms, which is leading to an increase in the challenges with the treatment. Therefore, the morbidity of the disease is high. To overcome this challenge, various organizations are conducting awareness campaigns at both regional level and global level. For instance. The Life Raft Group is a non-profit organization that focuses on providing information, educating medical professionals, and providing support to conduct innovative research for the treatment of gastrointestinal stromal tumors. The organization aims at reducing the time between the first appearance of the symptom to the diagnosis of the disease and between the diagnosis and the treatment. Similarly, the GIST Cancer Research Fund is another organization that is actively involved in increasing the awareness of the indication in the US. Hence, the growth in the number of awareness campaigns is leading to the increasing diagnosis of the disease during the early stages, which is resulting in more patients undergoing treatment on time, thus driving the market growth.

High treatment costs

A significant share of the global gastrointestinal stromal tumor’s therapeutics market is dominated by specialty drugs such as GLEEVEC, STIVARGA, and SUTENT. These drugs are priced very high when compared with traditional chemotherapy drugs due to their ability to target multiple proteins. Most of the patients, who do not have health insurance or access to patient assistance programs by vendors or governments, cannot afford the treatment using these drugs, which reduces the patient adherence and poses a challenge to the market growth. Also, the expected launch of various biologics is likely to increase the costs of treatment during the forecast period. The complex manufacturing process and high R&D costs of biologics often lead to vendors offering these drugs at a high price. These high treatment costs using therapeutics are expected to be one of the significant challenges to market growth during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the gastrointestinal stromal tumor’s therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated. The presence of a few companies, including Bayer AG and Bristol-Myers Squibb Co. makes the competitive environment quite intense. Factors such as the growing geriatric population and the increasing awareness campaigns will provide significant growth opportunities to the gastrointestinal stromal tumors therapeutics companies. Merck & Co. Inc., Novartis AG, and Pfizer Inc. are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY ROA

Market segmentation by RoA

Comparison by RoA

Oral – Market size and forecast 2018-2023

Parenteral – Market size and forecast 2018-2023

Market opportunity by RoA

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 14: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bayer AG

Bristol-Myers Squibb Co.

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

PART 15: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Global gastrointestinal stromal tumors therapeutics market pipeline: Overview

Exhibit 18: Global gastrointestinal stromal tumors therapeutics market pipeline: Snapshot

Exhibit 19: RoA – Market share 2018-2023 (%)

Exhibit 20: Comparison by RoA

Exhibit 21: Oral – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Oral – Year-over-year growth 2019-2023 (%)

Exhibit 23: Parenteral – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Parenteral – Year-over-year growth 2019-2023 (%)

Exhibit 25: Market opportunity by RoA

Exhibit 26: Customer landscape

Exhibit 27: Market share by geography 2018-2023 (%)

Exhibit 28: Geographic comparison

Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 30: North America – Year-over-year growth 2019-2023 (%)

Exhibit 31: Top 3 countries in North America

Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 34: Top 3 countries in Europe

Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Asia

Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in ROW

Exhibit 41: Key leading countries

Exhibit 42: Market opportunity

Exhibit 43: Global rise in geriatric population

Exhibit 44: Impact of drivers and challenges

Exhibit 45: Vendor landscape

Exhibit 46: Landscape disruption

Exhibit 47: Vendors covered

Exhibit 48: Vendor classification

Exhibit 49: Market positioning of vendors

Exhibit 50: Bayer AG – Vendor overview

Exhibit 51: Bayer AG – Business segments

Exhibit 52: Bayer AG – Organizational developments

Exhibit 53: Bayer AG – Geographic focus

Exhibit 54: Bayer AG – Segment focus

Exhibit 55: Bayer AG – Key offerings

Exhibit 56: Bayer AG – Key customers

Exhibit 57: Bristol-Myers Squibb Co. – Vendor overview

Exhibit 58: Bristol-Myers Squibb Co. – Business segments

Exhibit 59: Bristol-Myers Squibb Co. – Organizational developments

Exhibit 60: Bristol-Myers Squibb Co. – Geographic focus

Exhibit 61: Bristol-Myers Squibb Co. – Key offerings

Exhibit 62: Bristol-Myers Squibb Co. – Key customers

Exhibit 63: Merck & Co. Inc. – Vendor overview

Exhibit 64: Merck & Co. Inc. – Business segments

Exhibit 65: Merck & Co. Inc. – Organizational developments

Exhibit 66: Merck & Co. Inc. – Geographic focus

Exhibit 67: Merck & Co. Inc. – Segment focus

Exhibit 68: Merck & Co. Inc. – Key offerings

Exhibit 69: Merck & Co. Inc. – Key customers

Exhibit 70: Novartis AG – Vendor overview

Exhibit 71: Novartis AG – Business segments

Exhibit 72: Novartis AG – Organizational developments

Exhibit 73: Novartis AG – Geographic focus

Exhibit 74: Novartis AG – Segment focus

Exhibit 75: Novartis AG – Key offerings

Exhibit 76: Novartis AG – Key customers

Exhibit 77: Pfizer Inc. – Vendor overview

Exhibit 78: Pfizer Inc. – Business segments

Exhibit 79: Pfizer Inc. – Organizational developments

Exhibit 80: Pfizer Inc. – Geographic focus

Exhibit 81: Pfizer Inc. – Segment focus

Exhibit 82: Pfizer Inc. – Key offerings

Exhibit 83: Pfizer Inc. – Key customers

Exhibit 84: Validation techniques employed for market sizing

Exhibit 85: Definition of market positioning of vendors



【掲載企業】

Bayer AG
Bristol-Myers Squibb Co.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[消化管間質腫瘍治療の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆